Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

• Main Authors: Amy S. Paller (Author), Carsten Flohr (Author), Lawrence F. Eichenfield (Author), Alan D. Irvine (Author), Jamie Weisman (Author), Jennifer Soung (Author), Ana Pinto Correia (Author), Chitra R. Natalie (Author), Claudia Rodriguez Capriles (Author), Evangeline Pierce (Author), Sarah Reifeis (Author), Renata Gontijo Lima (Author), Clara Armengol Tubau (Author), Vivian Laquer (Author), Stephan Weidinger (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2023-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options for adolescents with moderate-to-severe disease. Lebrikizumab, a monoclonal antibody targeting interleukin (IL)-13, demonstrated clinical benefit in previous Phase 3 trials: ADvocate1...